APLT vs. CDMO, PBYI, RIGL, GTHX, PRTA, ZLAB, GLPG, KROS, PTGX, and EVO
Should you be buying Applied Therapeutics stock or one of its competitors? The main competitors of Applied Therapeutics include Avid Bioservices (CDMO), Puma Biotechnology (PBYI), Rigel Pharmaceuticals (RIGL), G1 Therapeutics (GTHX), Prothena (PRTA), Zai Lab (ZLAB), Galapagos (GLPG), Keros Therapeutics (KROS), Protagonist Therapeutics (PTGX), and Evotec (EVO). These companies are all part of the "pharmaceutical preparations" industry.
Avid Bioservices (NASDAQ:CDMO) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.
Avid Bioservices has higher revenue and earnings than Applied Therapeutics. Avid Bioservices is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.
97.2% of Avid Bioservices shares are held by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are held by institutional investors. 2.4% of Avid Bioservices shares are held by insiders. Comparatively, 8.6% of Applied Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Avid Bioservices received 296 more outperform votes than Applied Therapeutics when rated by MarketBeat users. Likewise, 66.49% of users gave Avid Bioservices an outperform vote while only 56.35% of users gave Applied Therapeutics an outperform vote.
Applied Therapeutics has a net margin of 0.00% compared to Applied Therapeutics' net margin of -13.10%. Applied Therapeutics' return on equity of -8.78% beat Avid Bioservices' return on equity.
Avid Bioservices currently has a consensus price target of $14.50, suggesting a potential upside of 82.16%. Applied Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 135.55%. Given Avid Bioservices' stronger consensus rating and higher possible upside, analysts clearly believe Applied Therapeutics is more favorable than Avid Bioservices.
In the previous week, Applied Therapeutics had 2 more articles in the media than Avid Bioservices. MarketBeat recorded 4 mentions for Applied Therapeutics and 2 mentions for Avid Bioservices. Applied Therapeutics' average media sentiment score of 1.46 beat Avid Bioservices' score of 0.54 indicating that Avid Bioservices is being referred to more favorably in the media.
Avid Bioservices has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500.
Summary
Applied Therapeutics beats Avid Bioservices on 10 of the 18 factors compared between the two stocks.
Get Applied Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Applied Therapeutics Competitors List
Related Companies and Tools
